Skip to main content
. 2021 Nov 16;11:751159. doi: 10.3389/fonc.2021.751159

Figure 4.

Figure 4

Kaplan-Meier estimates of over survival with advanced hepatocellular carcinoma who were treated with lenvatinib plus Nivolumab and pembrolizumab, respectively.